[{"id":"008ac45d-42cf-420e-ad02-8925f15a65fb","acronym":"","url":"https://clinicaltrials.gov/study/NCT04247126","created_at":"2021-01-18T20:38:36.579Z","updated_at":"2024-07-02T16:35:31.331Z","phase":"Phase 1","brief_title":"A Study of SY 5609, a Selective CDK7 Inhibitor, in Advanced Solid Tumors","source_id_and_acronym":"NCT04247126","lead_sponsor":"Syros Pharmaceuticals","biomarkers":" HER-2","pipe":" | ","alterations":" HR positive • HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • albumin-bound paclitaxel • fulvestrant • SY-5609"],"overall_status":"Completed","enrollment":" Enrollment 105","initiation":"Initiation: 01/23/2020","start_date":" 01/23/2020","primary_txt":" Primary completion: 01/31/2023","primary_completion_date":" 01/31/2023","study_txt":" Completion: 03/30/2023","study_completion_date":" 03/30/2023","last_update_posted":"2023-10-27"}]